Location: INSERM U932, Institut Curie, Paris, France

Date posted: April 2023

Application deadline: Until candidate is found

Starting date: september

Duration: 18 months to 3 years

Job description summary

The research group of Dr. Olivier Lantz (Inserm U932, Paris, France) is seeking an immunology and oncology postdoctoral fellow. The candidate will be dedicated to identify and validate novel tumor-specific neoantigens shared between cancer patients bearing metastatic uveal melanoma.


Institut Curie is one of the largest European institutions for cancer and biomedical research with strong interdisciplinary traditions. It is located in the center of Paris in France, in a both cultural and scientific rich environment. The site has active seminar program and hosts regular training sessions in molecular and cellular biology. The project will be developed in Center of Cancer Immunotherapy headed by Dr S. Amigorena and the Clinic Immunology Laboratory headed by Dr O. Lantz. The Immunology Department headed by Dr. AM Lennon includes 8 independent research teams in the fields of basic and applied immunology, working in a very collaborative and international environment. Candidate will work under the supervision of Dr. Olivier Lantz. The aim of the team is to characterize the biology of T cells, their interaction with other cells of the immune system, and their role in cancer, in both humans and through mice models. The open position is in line with recent developments at the interface between Immunology and Cancer (Bigot et al. Cancer Discovery, 2021). More information: www.curie.fr and http://u932.curie.fr/.


The project aims at characterizing tumor-specific T cells recognizing neo-Ag in human cancers. The in silico predicted neo-Ag will be further evaluated using immune-peptidomic. After definition of the most promising epitopes, the spontaneous response they induce in patients and their putative immunogenicity will be determined. The induction of an immune response in cancer patients under immunotherapy will be assessed in blood and tumor. Tumor specific T cells will be analyzed by flow cytometry, single cell RNAseq and functional assays. The candidate will work in close collaboration on this research program with two engineers.


  • PhD in immunology, molecular and cellular biology, or biothechnology
  • Knowledge in human immunology, oncology and immunotherapy
  • Expertise in flow cytometry is mandatory
  • Scientific rigor and excellent analytical and synthetic capabilities
  • Team spirit and dynamic personality with passion for innovation and problem-solving
  • Good proficiency in English


Please send your CV and motivation letter to [email protected]


Bigot J, Lalanne AI, Lucibello F,…Lantz O. Splicing Patterns in SF3B1-Mutated Uveal Melanoma Generate Shared Immunogenic Tumor-Specific Neoepitopes. Cancer Discov. 2021 Aug;11(8):1938-1951. doi:10.1158/2159-8290.CD-20-0555